These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8562961)

  • 1. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.
    Kuzel TM; Hurria A; Samuelson E; Tallman MS; Roenigk HH; Rademaker AW; Rosen ST
    Blood; 1996 Feb; 87(3):906-11. PubMed ID: 8562961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders.
    Kong LR; Samuelson E; Rosen ST; Roenigk HH; Tallman MS; Rademaker AW; Kuzel TM
    Leuk Lymphoma; 1997 Jun; 26(1-2):89-97. PubMed ID: 9250792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
    Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
    J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
    Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
    Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas.
    Canfield VA; Vose J; Guiney P; Bennett B; Nichols C
    Leuk Lymphoma; 1997 Jan; 24(3-4):335-9. PubMed ID: 9156663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
    Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
    Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
    Scarisbrick JJ; Child FJ; Clift A; Sabroe R; Whittaker SJ; Spittle M; Russell-Jones R
    Br J Dermatol; 2001 May; 144(5):1010-5. PubMed ID: 11359390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
    J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
    Gordon MS; Young ML; Tallman MS; Cripe LD; Bennett JM; Paietta E; Longo W; Gerad H; Mazza J; Rowe JM
    Leuk Res; 2000 Oct; 24(10):871-5. PubMed ID: 10996206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
    Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
    J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
    Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
    Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
    Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
    Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
    Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
    Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
    J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
    Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.